The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer
NCT ID: NCT04811079
Last Updated: 2025-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2021-07-14
2022-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
NCT05601544
Association Between Light Spectrum and Survival After Cataract Surgery
NCT04187157
Visual Performance of Senofilcon A With and Without a New UV/HEV-filter
NCT05021081
Effect of Blue Light Filtration on Visual Performance
NCT01938989
An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients
NCT01173198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spectacle Filter Sequence 1
(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 2
(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 3
(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 4
(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 5
(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 6
(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 7
(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 8
(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 9
(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Spectacle Filter Sequence 10
(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
419 nm Spectacle Filter
TEST
437 nm Spectacle Filter
TEST
456 nm Spectacle Filter
TEST
476 nm Spectacle Filter
TEST
373 nm Spectacle Filter
CONTROL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject must read and sign the Informed Consent form.
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Healthy adult males or females age ≥18 and ≤30 years of age.
4. Normal color vision as measured using the Ishihara 38-plate test.
5. Normal stereopsis as measured by a suitable test.
6. Auto-refraction must show a spherical component of -2.00 through +2.00 D, and a cylindrical component of 0.00 through 1.50 D.
7. The subject's distance refractive sphere must be between -2.00 and +2.00 D in each eye.
8. The subject's distance refractive cylinder must be ≤ 1.50 D in each eye.
9. The subject must have unaided distance Snellen visual acuity of 20/200 or better for each eye.
10. The subject must have best corrected distance Snellen visual acuity of 20/25 or better for each eye.
Exclusion Criteria
1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
2. History of refractive surgery or other ocular surgery.
3. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
4. Subjects that participated in the pilot study CR-6318.
5. Systemic conditions or the use of medications that the investigator believes will contraindicate participation in this study.
6. Abnormal Level 3 neuro-ophthalmology exam including crystalline lens clarity Grade 3 or worse (Lens Opacities Classification System).
7. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Slit Lamp Classification Scale.
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johnson & Johnson Vision Care, Inc. Clinical Trial
Role: STUDY_DIRECTOR
Johnson & Johnson Vision Care, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami Health - Bascom Palmer Eye Institute
Coral Gables, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-6402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.